RxDoctor Payments Data

Neda Motameni, MD

Internal Medicine · Miami, FLNPI 1184887895

Payments from drug & device makers

$8,294in general payments, 2019–2025

Across 456 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$984
  • Amgen$486
  • Pfizer$484
  • plus $3K from 33 others

What the payments were for

  • Food & beverage$8,264100%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,294 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$202,077
Medicare patients
267
Services billed
2,180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide51$80,023
TrulicityDulaglutide33$63,375
FarxigaDapagliflozin Propanediol46$57,545
JanumetSitagliptin Phos/Metformin Hcl32$49,916
MounjaroTirzepatide33$44,947
JardianceEmpagliflozin24$40,621
VascepaIcosapent Ethyl42$39,929
EliquisApixaban28$37,242
JanuviaSitagliptin Phosphate17$19,997
LinzessLinaclotide11$15,411
XifaxanRifaximin13$8,716
MyrbetriqMirabegron11$8,627
TradjentaLinagliptin11$8,462
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$5,889
Rosuvastatin Calcium274$5,501

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$984$108,32266 claims
Novo NordiskOzempic$1,121$80,02351 claims
MerckJanumet, Januvia$249$69,91349 claims
AstraZenecaFarxiga$1,026$57,54546 claims
Boehringer IngelheimJardiance, Tradjenta$374$49,08335 claims
PfizerEliquis$484$37,24228 claims
AbbVieLinzess, Synthroid$1,247$16,79022 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$27$8,71613 claims
Astellas Pharma US IncMyrbetriq$56$8,62711 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$51$1,513184 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →